Charles Duncan
Stock Analyst at Cantor Fitzgerald
(4.01)
# 578
Out of 4,712 analysts
254
Total ratings
43.32%
Success rate
13.45%
Average return
Main Sectors:
Stocks Rated by Charles Duncan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BHVN Biohaven | Reiterates: Overweight | n/a | $35.75 | - | 17 | Dec 17, 2024 | |
| AXSM Axsome Therapeutics | Reiterates: Overweight | $121 | $87.01 | +39.06% | 21 | Dec 12, 2024 | |
| STOK Stoke Therapeutics | Reiterates: Overweight | n/a | $11.32 | - | 7 | Dec 10, 2024 | |
| MRNS Marinus Pharmaceuticals | Reiterates: Overweight | $4 | $0.26 | +1,455.21% | 9 | Nov 14, 2024 | |
| HRMY Harmony Biosciences Holdings | Maintains: Overweight | $51 → $58 | $34.06 | +70.29% | 8 | Oct 30, 2024 | |
| ALKS Alkermes | Maintains: Overweight | $48 → $43 | $29.65 | +45.03% | 5 | Oct 25, 2024 | |
| CYTK Cytokinetics | Reiterates: Overweight | n/a | $48.53 | - | 7 | Oct 18, 2024 | |
| PRTA Prothena Corporation | Reiterates: Overweight | n/a | $15.40 | - | 15 | Sep 30, 2024 | |
| ITCI Intra-Cellular Therapies | Reiterates: Overweight | $130 | $85.24 | +52.51% | 21 | Sep 20, 2024 | |
| NBIX Neurocrine Biosciences | Reiterates: Overweight | $155 | $136.53 | +13.53% | 9 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $8.76 | - | 3 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $4.03 | - | 5 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $140 | $123.73 | +13.15% | 5 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $35 | $20.92 | +67.30% | 6 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $37 → $28 | $17.07 | +64.03% | 20 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $11 → $13 | $4.83 | +169.15% | 5 | Aug 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $9.53 | - | 6 | Jul 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $0.65 | - | 2 | Jul 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $7.32 | - | 3 | Jun 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $1.23 | - | 3 | Jun 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $34 | $21.62 | +57.26% | 9 | Mar 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $52 → $50 | $53.94 | -7.30% | 3 | Oct 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $5 | $4.18 | +19.62% | 1 | Sep 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $4 | $0.61 | +557.03% | 4 | Sep 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $4 | $0.76 | +423.35% | 4 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $58 | $38.42 | +50.96% | 3 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $110 | $2.15 | +5,016.28% | 4 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $80 | $5.00 | +1,500.00% | 5 | Aug 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $3 | $1.26 | +138.10% | 2 | Aug 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $16 → $11 | $10.87 | +1.20% | 2 | Dec 6, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $9 → $12 | $6.19 | +93.86% | 2 | Nov 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $146 → $168 | $8.51 | +1,874.15% | 6 | Jun 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $20 | $2.38 | +740.34% | 1 | Feb 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $200 | $13.87 | +1,341.96% | 3 | Feb 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $8 → $4 | $0.97 | +313.95% | 3 | Apr 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $24 | $2.34 | +925.64% | 1 | Oct 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $372 → $144 | $1.83 | +7,768.85% | 6 | Sep 28, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $3 → $4 | $3.34 | +19.76% | 2 | Jun 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $34 → $40 | $0.46 | +8,528.13% | 4 | May 19, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $35 → $39 | $47.54 | -17.96% | 4 | May 4, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $14 → $15 | $52.17 | -71.25% | 4 | Feb 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | n/a | $2.50 | - | 3 | Nov 15, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $180 | $7.55 | +2,284.11% | 1 | Oct 9, 2017 |
Biohaven
Dec 17, 2024
Reiterates: Overweight
Price Target: n/a
Current: $35.75
Upside: -
Axsome Therapeutics
Dec 12, 2024
Reiterates: Overweight
Price Target: $121
Current: $87.01
Upside: +39.06%
Stoke Therapeutics
Dec 10, 2024
Reiterates: Overweight
Price Target: n/a
Current: $11.32
Upside: -
Marinus Pharmaceuticals
Nov 14, 2024
Reiterates: Overweight
Price Target: $4
Current: $0.26
Upside: +1,455.21%
Harmony Biosciences Holdings
Oct 30, 2024
Maintains: Overweight
Price Target: $51 → $58
Current: $34.06
Upside: +70.29%
Alkermes
Oct 25, 2024
Maintains: Overweight
Price Target: $48 → $43
Current: $29.65
Upside: +45.03%
Cytokinetics
Oct 18, 2024
Reiterates: Overweight
Price Target: n/a
Current: $48.53
Upside: -
Prothena Corporation
Sep 30, 2024
Reiterates: Overweight
Price Target: n/a
Current: $15.40
Upside: -
Intra-Cellular Therapies
Sep 20, 2024
Reiterates: Overweight
Price Target: $130
Current: $85.24
Upside: +52.51%
Neurocrine Biosciences
Sep 16, 2024
Reiterates: Overweight
Price Target: $155
Current: $136.53
Upside: +13.53%
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $8.76
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $4.03
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: $140
Current: $123.73
Upside: +13.15%
Sep 9, 2024
Reiterates: Overweight
Price Target: $35
Current: $20.92
Upside: +67.30%
Aug 7, 2024
Maintains: Overweight
Price Target: $37 → $28
Current: $17.07
Upside: +64.03%
Aug 1, 2024
Maintains: Overweight
Price Target: $11 → $13
Current: $4.83
Upside: +169.15%
Jul 31, 2024
Reiterates: Overweight
Price Target: n/a
Current: $9.53
Upside: -
Jul 30, 2024
Downgrades: Neutral
Price Target: n/a
Current: $0.65
Upside: -
Jun 21, 2024
Reiterates: Overweight
Price Target: n/a
Current: $7.32
Upside: -
Jun 21, 2024
Reiterates: Overweight
Price Target: n/a
Current: $1.23
Upside: -
Mar 22, 2024
Reiterates: Overweight
Price Target: $34
Current: $21.62
Upside: +57.26%
Oct 24, 2023
Assumes: Overweight
Price Target: $52 → $50
Current: $53.94
Upside: -7.30%
Sep 22, 2023
Initiates: Overweight
Price Target: $5
Current: $4.18
Upside: +19.62%
Sep 7, 2023
Reiterates: Overweight
Price Target: $4
Current: $0.61
Upside: +557.03%
Aug 22, 2023
Reiterates: Overweight
Price Target: $4
Current: $0.76
Upside: +423.35%
Aug 22, 2023
Reiterates: Overweight
Price Target: $58
Current: $38.42
Upside: +50.96%
Aug 22, 2023
Reiterates: Overweight
Price Target: $110
Current: $2.15
Upside: +5,016.28%
Aug 16, 2023
Reiterates: Overweight
Price Target: $80
Current: $5.00
Upside: +1,500.00%
Aug 14, 2023
Reiterates: Overweight
Price Target: $3
Current: $1.26
Upside: +138.10%
Dec 6, 2022
Downgrades: Neutral
Price Target: $16 → $11
Current: $10.87
Upside: +1.20%
Nov 22, 2022
Upgrades: Overweight
Price Target: $9 → $12
Current: $6.19
Upside: +93.86%
Jun 8, 2022
Maintains: Overweight
Price Target: $146 → $168
Current: $8.51
Upside: +1,874.15%
Feb 18, 2022
Initiates: Overweight
Price Target: $20
Current: $2.38
Upside: +740.34%
Feb 18, 2022
Initiates: Overweight
Price Target: $200
Current: $13.87
Upside: +1,341.96%
Apr 20, 2021
Downgrades: Neutral
Price Target: $8 → $4
Current: $0.97
Upside: +313.95%
Oct 23, 2020
Initiates: Overweight
Price Target: $24
Current: $2.34
Upside: +925.64%
Sep 28, 2020
Downgrades: Neutral
Price Target: $372 → $144
Current: $1.83
Upside: +7,768.85%
Jun 1, 2020
Maintains: Overweight
Price Target: $3 → $4
Current: $3.34
Upside: +19.76%
May 19, 2020
Reiterates: Overweight
Price Target: $34 → $40
Current: $0.46
Upside: +8,528.13%
May 4, 2020
Reiterates: Overweight
Price Target: $35 → $39
Current: $47.54
Upside: -17.96%
Feb 21, 2020
Reiterates: Neutral
Price Target: $14 → $15
Current: $52.17
Upside: -71.25%
Nov 15, 2017
Upgrades: Overweight
Price Target: n/a
Current: $2.50
Upside: -
Oct 9, 2017
Initiates: Overweight
Price Target: $180
Current: $7.55
Upside: +2,284.11%